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REVIEW
ANIMAL MODELS FOR THE STUDY OF LEISHMANIASIS IMMUNOLOGY
Elsy Nalleli LORÍA-CERVERA & Fernando José ANDRADE-NARVÁEZ
SUMMARY
Leishmaniasis remains a major public health problem worldwide and is classified as Category I by the TDR/WHO, mainly due to 
the absence of control. Many experimental models like rodents, dogs and monkeys have been developed, each with specific features, 
in order to characterize the immune response to Leishmania species, but none reproduces the pathology observed in human disease. 
Conflicting data may arise in part because different parasite strains or species are being examined, different tissue targets (mice 
footpad, ear, or base of tail) are being infected, and different numbers (“low” 1x102 and “high” 1x106) of metacyclic promastigotes 
have been inoculated. Recently, new approaches have been proposed to provide more meaningful data regarding the host response 
and pathogenesis that parallels human disease. The use of sand fly saliva and low numbers of parasites in experimental infections 
has led to mimic natural transmission and find new molecules and immune mechanisms which should be considered when designing 
vaccines and control strategies. Moreover, the use of wild rodents as experimental models has been proposed as a good alternative 
for studying the host-pathogen relationships and for testing candidate vaccines. To date, using natural reservoirs to study Leishmania 
infection has been challenging because immunologic reagents for use in wild rodents are lacking. This review discusses the principal 
immunological findings against Leishmania infection in different animal models highlighting the importance of using experimental 
conditions similar to natural transmission and reservoir species as experimental models to study the immunopathology of the disease.
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INTRODUCTION
Leishmaniasis encompasses a group of diseases which are caused by 
infection with protozoan parasites of the Leishmania (Kinetoplastida: 
Trypanosomatidae) genus. They are still a major worldwide public 
health problem considering they are endemic in 98 countries or 
territories, with more than 350 million people at risk6. Moreover, it 
is estimated visceral leishmaniasis (VL) causes over 50,000 deaths 
annually, a rate only surpassed, among parasitic diseases, by malaria, 
and 2,357,000 disability-adjusted life years lost, placing leishmaniasis 
ninth in a global analysis of infectious diseases6,28. Despite this 
very strong data, leishmaniasis is largely ignored in discussions of 
tropical disease priorities and is one of the most neglected tropical 
diseases51,52. It has been pointed out that this consignment to critical 
oblivion possibly “results from its complex epidemiology and ecology, 
the lack of simple, easily-applied tools for case management and the 
paucity of current incidence data, and often results in a failure on the 
part of policy-makers to recognize its importance5,14. Political and 
socioeconomic changes may have an even more important role than 
global warming on the changing epidemiology of the leishmaniases, 
as has been argued for tick-borne diseases in Europe91. The European 
Centre for Disease Prevention and Control lists the leishmaniases among 
the ten vector-borne diseases that have the greatest potential to affect 
European inhabitants101.
The disease is transmitted to humans by sand flies and displays 
different clinical manifestations, ranging from asymptomatic or 
subclinical infection to disfiguring forms of cutaneous and mucosal 
leishmaniasis or potentially fatal visceral disease35,36,78,93. This 
polymorphic outcome has been considered to depend largely on the 
virulence of the infecting parasite strain, immunoregulatory effects of 
sand fly saliva, as well as the host’s genetic background and immune 
response31,60,62. In summary, the leishmaniases remain as unpreventable 
and uncontrollable diseases; moreover, their epidemiological profile is 
shifting towards an increased prevalence, and therefore novel instruments 
and approaches to reach their control are urgently necessary.
Leishmaniasis is most likely to be controlled by a successful 
vaccination program. The relatively uncomplicated leishmanial life 
cycle and the fact that recovery from a primary infection renders the host 
resistant to subsequent infections indicate that a vaccine is feasible55. 
Many immunological aspects of the disease have been studied in 
experimental animal models, such as mice, hamsters, domestic dogs 
and non-human primates. Although most experimental models of 
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leishmaniasis have the major advantage of allowing control over the 
genetics of both the parasite and the host, none of them, in any way, 
reproduces the outcome of human infection by Leishmania spp49.
Among the main factors contributing to differences between humans 
and animal models are the size and nature of the inocula, the infection 
route and the strain of host or parasite37,60,70. Currently, small numbers of 
in vitro-derived metacyclic promastigotes together with strongly bioactive 
saliva, intradermal infection and host reservoirs as experimental animal 
models are used to mimic the clinical and immunological features found 
in human disease49. These approaches could contribute to developing 
improved experimental models for studying leishmaniasis and identifying 
possible targets to evaluate vaccine candidates.
The present review describes the most common animal experimental 
models which have been employed to study the immune response to 
Leishmania spp. and includes wild rodents. The main purpose is to 
discuss the concept of experimental animal models to study leishmaniasis 
immunology.
MOUSE MODEL
The laboratory mouse owes much of its popularity as a model 
organism in biomedical research to the existence of a large collection of 
inbred strains that represent an immortal population of genetic clones 
derived by repeated brother sister mating. Because mice from each strain 
are genetically identical it is possible to collect and combine biological 
data over time and space leading to a depth of phenotype characterization 
rarely achieved in other mammalian systems. Furthermore, the existence 
of a definite set of genetic differences among inbred strains allows 
scientists to explore the effect of genetic diversity on almost any 
phenotype of interest107. Another advantage of the murine model is the 
simplicity of keeping, breeding and reproducing them47.
During the past 40 years, murine models of the human disease 
cutaneous leishmaniasis have been extensively employed to elucidate the 
cell types, cytokines, signal transduction cascades and antileishmanial 
effector mechanisms that are necessary for the control of parasites, as 
well as for the clinical resolution of disease, resistance to a secondary 
infection, and vaccine development18,73. Experimental infection of 
mice with L. major promastigotes has allowed understanding of the 
immunologic mechanisms governing resistance (C57BL/6 strain) and 
susceptibility (BALB/c strain) to infection2.
Susceptibility has been correlated with the development of lesions 
associated with a Th2 type of immune response, while the healing of 
lesions in resistant mice has been correlated with the development of a 
Th1 type of immune response98. The resolution of lesions in C57BL/6 
mice has been shown to involve several factors contributing to the killing 
of L. major within macrophages. The most efficient mechanism of 
parasite killing involves the production of gamma interferon (IFN-γ) and 
tumor necrosis factor alpha (TNF-α) by CD4+ Th1 cells, which stimulate 
the synthesis of inducible nitric oxide synthase (iNOS), generating the 
production of nitric oxide (NO), a potent cytotoxin involved in the 
clearance or inhibition of Leishmania parasites61,65,77.
In contrast, susceptible BALB/c mice develop severe and uncontrolled 
lesions that lead to progressive disease and eventual death. This non-
healer phenotype has been shown to be associated with a parasite-specific 
Th2 response characterized by the enhanced expression of deactivating 
macrophage cytokines such as interleukin 4 (IL-4), interleukin 10 (IL-
10) and transforming growth factor-β (TGF-β)11,94,98,. Studies of mouse 
models of leishmaniasis have provided important insights into the 
response of the host to infection. However, the use of different parasite 
species, tissue targets (mice footpad, ear, or base of tail) and doses (105 
to 107) of metacyclic promastigotes has generated a wide variety of 
experiments that do not reproduce the natural infection and cannot be 
extrapolated to human disease.’
In natural infections, the sand fly introduces into the skin a very small 
number (possibly as few as 100 to 1,000) of metacyclic promastigotes 
together with strongly bioactive saliva, whereas in laboratory infections 
thousands to millions of culture-derived promastigotes or tissue-derived 
amastigotes are injected with a saline solution or culture medium57.
In order to have a better understanding of natural Leishmania 
infection in the laboratory, investigators are now using small numbers 
of in vitro-derived metacyclic promastigotes and intradermal rather than 
subcutaneous infection into the ears of mice49.
It was demonstrated, for example, that in mice inoculated with a 
mixture of phlebotomine saliva and L. major promastigotes, the lesions 
grew faster and were bigger than those of mice inoculated only with 
promastigotes13.
The ability of saliva to enhance Leishmania infection has been 
attributed to modulation of the host immune system, potentially 
through anti-inflammatory properties such as down regulation of 
antigen presentation, co-stimulatory molecule expression, and nitric 
oxide production13, 81. However, vaccination by pre-exposure to the 
bites of uninfected sand flies, with whole saliva or with defined salivary 
proteins has shown to protect against cutaneous L. major infection97. 
The frequent exposure to sand fly bites leads to the production of 
neutralizing antibodies against salivary proteins and also to the activation 
of cellular mechanisms that may have an adverse effect on Leishmania 
establishment. In this perspective, characterization of immune responses 
against sand fly saliva can help estimate both risk of infection and, to some 
degree, anti-parasite immunity. Although this hypothesis has been proven 
in animal models, additional large-scale clinical studies are necessary 
to validate it in humans15. Although the regulation of host immune 
response to Leishmania has been well defined in cutaneous L. major 
infection of inbred mice, many studies have demonstrated that the host 
responses within the same mouse strain could vary according to different 
Leishmania species. Different virulence factors have been identified for 
distinct Leishmania species, and there are profound differences in the 
immune mechanisms that mediate susceptibility/resistance to infection 
and in the pathology associated with disease66. For example, C57BL/6 or 
C3H mice, which heal from L. major infection, develop chronic disease 
when infected with either L. (L.) amazonensis or L. (L.) mexicana.
The characteristic chronic lesions of L. (L.) amazonensis infection 
in C57BL/6 and C57BL/10 mice are independent of IL-4 expression 
and corresponding Th2 response1,54. In addition, L. (L.) amazonensis 
infection in C3H mice results in low levels of production of IL-12 and 
IFN-γ by antigen-specific CD4+ T cells54. However, lesion development 
and parasite burden have been shown to be exacerbated in the presence 
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of CD4+ T cells, demonstrating that T cells are activated during L. 
(L.) amazonensis infection and that they contribute significantly to the 
immunopathology of chronic disease103.
Recently, it was demonstrated that susceptibility to L. (L.) 
amazonensis in the mouse model of cutaneous leishmaniasis does not 
depend only on the expression of IL-10. L. (L.) amazonensis parasites 
persistent in IL-10-deficient mice; even in the presence of an enhanced 
Th1 response during the early stages of infection and in the presence 
of antigen-specific cells primed for Th1 effectors function during the 
chronic phase53.
Although the requirements for effective intracellular killing of L (L.) 
amazonensis by activated macrophages are relatively unknown, it has 
been demonstrated that the presence of both superoxide and nitric oxide is 
necessary for efficient killing of amastigotes within LPS/IFN-γ–activated 
bone marrow-derived macrophages generated from C3H mice74.
Control of the closely related L. (L.) mexicana in C57BL/6 mice 
has been shown to be IFN-γ and STAT4-dependent and surprisingly 
independent of IL-12 production while the presence of IL-4, STAT6 
and, perhaps as a consequence, the ability to generate Th2 responses, 
are essential for the rapid lesion growth and nonhealing responses21,100,106. 
Later on, it was demonstrated that endogenous IL-12 is only critical for 
controlling the late but not the early stage of L. (L.) mexicana infection 
in C57BL/6 mice; however, they fail to resolve lesions, in contrast to L. 
major infection3.
As an evasion mechanism, L. (L.) mexicana promastigotes mediate 
the phosphorylation of specific transcription factors to enhance iNOS, 
COX-2 and arginase-1 expression in LPS induced macrophages via 
TLR-4. The activities associated with all three enzymes are the main 
factors leading to the downregulation of the IL-12 production in L. (L.) 
mexicana infected macrophages102. 
The significant differences in the immune response between the 
Old World (L. major) and New World (L. mexicana/L. amazonensis) 
Leishmania species not only point to interesting features of the 
host-pathogen interaction and immunobiology of this genus of parasitic 
protozoa, but also have important implications for immunotherapy 
and vaccine development. A view of leishmaniasis that only considers 
mouse model infection with L. major misses a wealth of interesting 
immunobiology associated with other species of Leishmania66. Therefore, 
our understanding of the mechanisms involved in mucocutaneous and 
cutaneous diseases caused by these organisms remains limited.
Mouse models have also been used to study visceral leishmaniasis 
caused by both L. donovani and L. infantum. Although the outcome of 
murine VL infection is genetically determined, most susceptible mouse 
strains including BALB/c are able to control visceral disease75. Following 
Leishmania infection, BALB/c mice develop an organ-specific immune 
response113. During the first weeks of infection, the parasites multiply 
rapidly in the liver; however four weeks later, the mice develop an 
effective Th1 immune response, clear the parasites and become resistant 
to reinfection76. The hepatic resistance to Leishmania infection in these 
mice is associated with the development of a granulomatous reaction in 
the liver12. While pathology in the liver is limited, the parasites persist 
in the spleen and the infection progresses for a longer period of time. 
Eventually, splenic replication is controlled but parasites are usually 
maintained for life58. Parasite persistence in mice is accompanied by 
failure of granuloma formation and splenomegaly39.
Due to the fact that visceral infection in BALB/c mice is chronic 
but not fatal, it may be more appropriate to use it as a model for 
studying self-healing or subclinical infection. Although experimental 
murine models of VL do not allow exact extrapolations with subclinical 
infection in humans they have been useful to identify genes and predict 
their functional roles in the protective immune response. Genetically 
resistant mice have the functional NRAMP1 gene which is involved in 
macrophage activation16. The NRAMP1 gene encodes a protein expressed 
on the membrane of infected macrophages and exerts an enhanced effect 
on iNOS expression and generation of NO, restricting intracellular 
Leishmania multiplication17. In this context, visceral infection in BALB/c 
mice provides a good model for the evaluation of candidate vaccines.
HAMSTER MODEL
The Syrian golden hamster (Mesocricetus auratus) is highly 
susceptible to infection with visceralizing Leishmania species (L. 
donovani, L. infantum) and is considered the best experimental 
model to study visceral leishmaniasis (VL) because it reproduces the 
clinicopathological features of human disease. However, the wide use of 
hamsters is still limited due to the scarcity of reagents (e.g., antibodies, 
cell markers and cytokines) of defined specificity available to study the 
role of the immune response in disease pathology48,68,113.
In 1978, CHANG & DWYER provided quantitative evidence 
indicating an avid ingestion of L. donovani amastigotes by hamster 
macrophages and supported the early findings that lysosome-phagosome 
fusion ocurrs26. 
In order to understand the immune response to L. donovani infection 
the nucleotide sequences of several hamster cytokine genes (IL-2, IL-4, 
INF-γ, TNF-α, IL-10, IL-12 and TGF-β) were cloned and used to analyze 
their expression in a model of visceral infection. In this hamster model 
there was a pronounced expression of the Th1 cytokine mRNAs (IL-2 
and IFN-γ), with transcripts being detected as early as one week post-
infection. Surprisingly, although the basal expression of IL-4 was detected 
in uninfected hamsters, their expression did not increase in response to 
infection with L. donovani. IL-12 transcript expression was detected at low 
levels starting seven days post-infection and its expression paralleled that of 
IFN-γ. Additionally, the mRNA for TNF-α was increased within one week 
of infection but levels did not increase further during the first month of 
infection. Expression of IL-10, a potent macrophage deactivator, increased 
in splenic tissue over the first four weeks after infection, suggesting that 
this cytokine could contribute to progressive disease in hamsters. These 
studies provided the first description of the molecular immunopathogenesis 
of disease in hamsters and indicated that progressive disease in this model of 
VL is not associated with early polarization of the splenic cellular immune 
response toward a Th2 phenotype and away from a Th1 phenotype, offering 
important insights into human disease67.
During progressive disease in the hamster model of VL, uncontrolled 
parasite replication in the liver, spleen, and bone marrow occurred despite 
the high activation of the immune response and the strong Th1-like 
cytokine microenvironment. The failure in the control of VL could be 
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partially explained by the lymphoproliferative suppression process which 
occurs during active disease45. Visceral infection caused by L. donovani 
led to a gradual impairment of the proliferative response to parasite 
antigens in hamsters79. The latter dysfunction has been attributed to the 
inability of the infected antigen-presenting cells (APCs) to stimulate 
specific T cells, the production of TGF-β which triggers the apoptotic 
death of lymphocytes and the downregulation of protein kinase C 
activity9,72,95. Interestingly, the antigen-dependent immunosuppression 
observed in L. chagasi-infected hamsters with active visceral disease is 
not related to the cytokine profile41.
Furthermore, the fatal outcome of the disease in the hamster model 
has been related to the loss of macrophages effector functions. Indeed, 
throughout the course of infection, inducible NO synthase (iNOS, NOS2) 
mRNA or enzyme activity in liver or spleen tissue was not detected. 
Thus, although a Th1-like cytokine response was prominent, the major 
antileishmanial effector mechanism that is responsible for control of 
infection in mice was absent throughout the course of progressive VL 
in the hamster68.
Later on, it was shown that the lack of NO production was due to 
a defect in the transcriptional activation of NOS2. Luciferase reporter 
assays demonstrated that the hamster NOS2 promoter, like the human 
NOS2 promoter, has reduced basal and IFN-γ/LPS-induced activity 
compared with the mouse promoter. The mechanism described above 
is the most probable reason for the inability of hamsters to control 
Leishmania infection84.
The role played by infected macrophages in the development of the 
cellular unresponsiveness present in visceral leishmaniasis has been 
studied. Adherent spleen cells from infected hamsters were unable to 
present L. donovani antigens to antigen specific T cells, however they 
were able to present KLH. Conversely, T cells from infected animals did 
not respond to parasite antigens even when these antigens were presented 
by normal syngeneic macrophages. Interestingly, lymphocytes from 
inguinal lymph nodes of infected animals sensitized in their footpad 
with parasite antigens proliferated well when stimulated in vitro with 
L. donovani antigens. These results suggest that the defect in the cellular 
immune response of the L. donovani infected hamsters is a consequence 
of a selective inability of their antigen presenting cells to process and 
present parasite antigens to T cells95.
To date, progressive disease in hamsters has been mostly achieved 
by the injection of a large number of parasites via the i.v., intracardial, 
or i.p. routes. However, these routes of infection do not mimic natural 
transmission by sand fly bite where the parasites are delivered into the 
skin of a mammalian host in the presence of saliva. Recently, it was 
demonstrated that a salivary protein of the sand fly vector Lutzomia 
longipalpis protects against the fatal outcome of visceral leishmaniasis 
caused by L. infantum in a hamster model. Immunization with 16 DNA 
plasmids coding for salivary proteins of Lu. longipalpis resulted in the 
identification of LJM19, a novel 11-kDa protein, that protected hamsters 
against the fatal outcome of VL. LJM19-immunized hamsters maintained 
a low parasite load that correlated with an overall high IFN-γ/TGF-β 
ratio and iNOS expression in the spleen and liver up to five months 
postinfection. Importantly, a delayed-type hypersensitivity response with 
high expression of IFN-γ was also noted in the skin of LJM19-immunized 
hamsters 48 hours after exposure to uninfected sand fly bites. Induction of 
IFN-γ at the site of the bite could partly explain the protection observed in 
the viscera of LJM19-immunized hamsters through direct parasite killing 
and/or priming of anti-Leishmania immunity. These findings reinforce 
the concept of using components of arthropod saliva in vaccine strategies 
against vector-borne diseases44.
To better understand the hamster immune response to important 
pathogens such as Leishmania, a duplex real-time reverse transcriptase (RT) 
PCR assay was developed for the relative quantification of the mRNAs of 
hamster cytokines, chemokines, and related immune response molecules. 
The application of this assay to a biological model was demonstrated 
in a cutaneous hamster model by comparing mRNA expression in skin 
and lymph node tissues between uninfected and L. panamensis infected 
hamsters. As a result, there was a relatively greater basal expression in 
the LN compared to the skin for most transcripts (IL-4, CCR4, IL-21, 
TNF-α, TGF-β, IFN-γ, IL-12p40, IL-10, and Foxp3). Conversely, the assay 
identified that the basal expression of CCL22 and CCL17 mRNAs was 
significantly greater in the normal skin compared to the LN. At an early 
stage of infection(one week p.i. ) there was concomitant upregulation of 
the type 1 (IFN-γ and IL-12p40) and type 2 (IL-4, IL-10, IL-13, and IL-21) 
cytokines at the site of cutaneous infection, suggesting that a balanced type 
1 and type 2 cytokine response contributes to the chronicity of the disease 
caused by L. panamensis in hamsters40.
Undoubtedly, the hamster model may be helpful for understanding 
the immunological mechanisms involved in the pathogenesis of 
visceral leishmaniasis. However, it is necessary to continue the efforts 
of producing specific reagents (i.e. cytokine-specific and cell surface 
markers of monoclonal antibodies) and develop more sensitive techniques 
that allow the study of the immunopathogenesis of the disease, which 
has important implications for the generation of therapeutic and vaccine 
targets.
DOG MODEL
Wild canines and domestic dogs are the main reservoirs of zoonotic 
visceral leishmaniasis caused by L. infantum in the Mediterranean area, 
Middle-East, Asian countries and Latin America. The role of dogs as the 
main reservoir of visceral leishmaniasis has led to an increased interest in 
studying the immune response and finding Leishmania antigens implicated 
in protective cellular immunity in canine visceral leishmaniasis. Recent 
research has provided new insights on the epidemiology, pathology 
and immunology of canine leishmaniasis and its genetic basis. These 
new findings have led to better understanding of the disease, and have 
also helped in the development of new diagnostic methods and control 
measures against the infection, such as insecticide-impregnated collars 
for dogs, new drugs, and second generation vaccines4,10.
Canine visceral leishmaniasis is a multisystemic disease with variable 
clinical signs. Infected dogs may develop symptomatic infection resulting 
in death, while others remain asymptomatic, or develop one or more 
mild symptoms and are classified as oligosymptomatic27. The typical 
histopathological finding in the skin, liver and spleen, is a granulomatous 
inflammatory reaction associated with the presence of Leishmania 
amastigotes within macrophages10.
Studies on experimentally infected dogs have demonstrated that 
three years after infection, asymptomatic or resistant dogs responded to 
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L. infantum antigen both in lymphocyte proliferation assays in vitro and 
in delayed-type hypersensitivity reaction, whereas no serum antibodies 
to parasite antigen were shown. In contrast, symptomatic or susceptible 
animals failed to respond to the parasite antigen in cell-mediated 
assays both in vitro and in vivo and showed considerably higher serum 
antibodies to leishmanial antigens, which are not immunoprotective. In 
addition, peripheral mononuclear cells from asymptomatic dogs produced 
significantly higher levels of IL-2 and TNF-α than symptomatic and 
control uninfected dogs. Similar results were observed with a group of 
mixed-breed dogs with natural Leishmania infections, also grouped as 
asymptomatic or symptomatic on the basis of clinical signs of canine 
visceral leishmaniasis85.
The main effector mechanism involved in the protective immune 
response of dogs infected with L. infantum is the activation of 
macrophages by IFN-γ and TNF-α to kill intracellular amastigotes via 
the L-arginine nitric oxide pathway, as has been observed following 
successful chemotherapy of L. infantum-infected dogs112. NO 
production and anti-leishmanial activity has also been detected in a 
canine macrophage cell line infected with L.infantum after incubation 
with IFN-γ, TNF-α and IL-288, as well as in macrophages from dogs 
immunized with killed L.infantum promastigotes82. Later on, it was 
demonstrated that NO production may be involved in the long-term 
protection of dogs against natural Leishmania infection and in the clinical 
presentation of canine leishmaniasis83.
The local tissue cytokine response of dogs naturally infected with L. 
infantum has been evaluated. The analysis revealed an enhanced INF-γ 
mRNA accumulation in infected dogs which was positively correlated 
with humoral, (IgG1) but not with lymphoproliferative, responses to the 
Leishmania antigen. However, infected dogs with detectable IL-4 mRNA 
had significantly more severe symptoms90. A balanced production of Th1 
and Th2 cytokines was detected in the spleen of L. infantum infected dogs, 
with a predominant accumulation of mRNA for IL-10 and IFN-γ that was 
related to the parasitic load and to clinical progression59. Additionally, a 
mixed cytokine profile with high levels of expression of IFN-γ, TNF-α 
and IL-13 was determined in the skin of asymptomatic dogs naturally 
infected with L. infantum. Moreover, the levels of transcription factors 
GATA-3 and FOXP3 were correlated with the asymptomatic disease. 
These results indicate that in addition to the mixed cytokine profile, 
the enhanced expression of their associated transcription factors plays 
an important role in the clinical status of Leishmania infected dogs69. 
The role of Th2 type cytokines in canine VL has not yet been defined. 
Evidence for Th1 and Th2 mixed responses has been reported in antigen-
stimulated PBMC from asymptomatic dogs experimentally infected 
with L. infantum, which displayed IL-2, IFN-γ and IL-10 mRNA 
transcripts. However, IL-2 and IFN-γ predominated in asymptomatic 
dogs and the development of symptomatic infections could not be 
related to IL-10 expression25. IL-10 mRNA transcripts were detected in 
Con A-stimulated PBMC derived from dogs with clinical signs of VL87. 
All of these results are in agreement with experiments in which PBMC 
obtained from symptomatic VL dogs were stimulated by a recombinant 
L. infantum cysteine proteinase and high levels of IL-10 were detected 
by an ELISA assay. In contrast, low or undetectable concentrations of 
this cytokine were found in PBMC supernatants from oligosymptomatic 
and asymptomatic animals, respectively89.
Although IL-10 secreted by CD25+ CD4+-regulatory T cells has 
been implicated in murine and human leishmaniasis, the involvement 
of these cells in canine visceral leishmaniasis has not been explored.
Few studies have demonstrated the involvement of CD8+ 
lymphocytes in resistance to canine VL. These lymphocytes were detected 
in asymptomatic dogs experimentally infected with L.infantum but not in 
symptomatic animals, suggesting that direct lysis of L. infantum-infected 
macrophages by cytotoxic T lymphocytes represents an additional 
effector mechanism in resistance to VL86. In dogs naturally infected 
with L. infantum, a reduction in both CD4+ and CD8+ populations was 
observed, while restoration of these cells occurred after drug treatment19.
The use of dogs as experimental models to study visceral leishmaniasis 
has led to elucidate the role of immune cells and their principal products 
to better understand the possible mechanisms mediating immune response 
during Leishmania infection, which may contribute to the development 
of vaccines or immunotherapy.
Natural infection of domestic dogs with L. (V.) braziliensis, L. (V.) 
peruviana, L. (V.) panamensis, L. (V.) colombiensis and L. (L.) mexicana 
has been reported in Latin America30. To date, there is no solid evidence 
that dogs act as reservoir hosts for the domestic transmission of CL92,99. 
Most studies are designed to determine the prevalence of CL in dogs, 
however, little is known about the parasitologic and immunologic course 
of infection.
NON-HUMAN PRIMATE MODEL
Non-human primates are valuable models for biomedical research 
because of their similarities to humans in anatomy, immunology and 
physiology. However, they are expensive laboratory animals that are 
difficult to obtain and to handle. Availability of a non-human primate 
model of leishmaniasis would facilitate the study of different aspects 
of this disease and would accelerate the development of vaccines and 
testing of new drug candidates.
The Asian rhesus macaques (Macaca mulatta) are quite susceptible 
to Leishmania infection: they develop a human-like disease, exhibit 
antibodies to Leishmania and parasite-specific T-cell mediated immune 
responses both in vivo and in vitro, and can be protected effectively 
by vaccination46. Distinct histopathological patterns were observed in 
Macaca mulatta lesions at biopsy, but healing lesions contained more 
organized epithelioid granulomas and activated macrophages, followed 
by fibrotic substitution in response to L. (L.) amazonensis infection7. 
Interestingly in L. (V.) braziliensis infection, the presence of antigen-
specific IFN-γ or TNF-α-producing CD4+ and CD8+ cells are likely 
important for the immunological effectiveness of granulomas. However, 
their resolution can be attributed to the concomitant recruitment of IL-
10-producing CD4+CD25+ regulatory T cells that suppress the effector 
T-cell mediated inflammatory response32,105. The progression and 
resolution of skin lesions caused by both Leishmania species appears 
to be very similar to that observed in humans, confirming the potential 
for this monkey as a viable surrogate to study the immune response in 
human cutaneous leishmaniasis7.
Macaques have also been used to explore immune response against 
L. major infection. Infected animals develop a simple cutaneous lesion 
which progresses spontaneously to ulceration and complete resolution 
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within about three months which is associated with a non-specific 
chronic inflammation and/or tuberculoid-type granulomatous reaction. 
Additionally, macaques develop varying levels of resistance against 
homologous re-infection as it happens in humans. Thus, the importance 
of this model in experimental CL lies in the reproduction of clinical and 
histopathological features that are common in L. major-infected humans 
and in the resistance to secondary infection, indicating the development 
of an acquired immunity8.
New World primates, such as owl monkeys (Aotus trivirgatus), 
squirrel monkeys (Saimiri sciureus), and marmosets (Callithrix jaccus 
jaccus) have been considered potential hosts for studying visceral 
leishmaniasis. Owl monkeys develop a visceral disease characterized by 
weight loss, anemia and hepatosplenomegaly. Its high susceptibility to 
L. donovani infection suggest it may be useful for the study of VL20. In 
contrast, squirrel monkeys develop a visceral disease when infected with 
L. donovani but are able to recover from disease and became resistant 
to reinfection34.
Although little is known about immune response to Leishmania 
infection in monkeys, they are frequently used as models for preclinical 
testing of Leishmania candidate vaccines. The safety, immunogenicity, 
and efficacy of a vaccine combining heat-killed L. (L.) amazonensis 
with human rIL-12 (rhIL-12) and alum (aluminium hydroxide gel) 
as adjuvants was evaluated in rhesus macaques. The single s.c. 
vaccination was found to be safe and immunogenic, although a small 
transient s.c. nodule developed at the vaccination site. Groups receiving 
rhIL-12 had an augmented in vitro Ag-specific IFN-γ response after 
vaccination, as well as increased production of IgG. Furthermore, 
intradermal forehead challenge infection with 107 metacyclic L. (L.) 
amazonensis promastigotes at four weeks demonstrated protective 
immunity in all monkeys receiving rhIL-12 with alum and Ag. Thus, 
a single dose vaccine with heat-killed Leishmania using rhIL-12 and 
alum as adjuvants was safe and fully protective in a primate model of 
cutaneous leishmaniasis56.
Successful vaccination has been achieved against visceral 
leishmaniasis by intradermal inoculation of alum-precipitated autoclaved 
L. major with BCG (bacile Calmette-Guérrin) and autoclaved L. donovani 
with BCG in Indian langurs. Vaccinated animals show a delayed 
protection and significant lymphoproliferative response with high levels 
of IFN-γ and IL-238,71.
Attempts were made to reproduce the spectrum of human visceral 
leishmaniasis due to L. donovani in Vervet monkeys (Chlorocebus 
pygerythrus). Both symptomatic and asymptomatic/cryptic infections 
were observed. However asymptomatic infected animals had competent 
humoral and cellular responses to homologous parasites43. 
The development of a non-human primate model of leishmaniasis, 
which largely mimics the human situation, is described for studies of 
different aspects of the disease that would not be possible in humans 
for ethical reasons. However, for financial and ethical reasons, the use 
of primates in biomedical research is limited. Studies involving these 
animals have, therefore, been tailored to solve questions that cannot be 
answered in other animals. Monkeys are normally the final experimental 
animals to be used in studies of the safety and efficacy of vaccines and 
drugs developed in other laboratory animals48.
WILD RODENTS
Classical laboratory inbred strains of mice have been extremely 
helpful for research in immunology and oncology. Unfortunately, because 
they all derive from a relatively small pool of ancestors, their genetic 
polymorphism is rather limited47.
A new approach to study host-parasite relationships has been the 
use of wild rodents, particularly primary reservoirs, as experimental 
animal models. They are, as the human being, genetically polymorphic 
and represent an emerging system for the genetic analyses of the 
physiological and behavioral bases of habitat adaptation47. Laboratory 
studies using natural hosts as experimental models provide a suitable 
indication of the importance of these hosts as reservoirs, since it allows a 
better understanding of the dynamics of infection, especially concerning 
the ability to retain the infection and amplify parasite populations in a 
given environment, due to features that favor parasite transmission (e.g., 
presence of parasites in the skin). Moreover, the study of these rodents 
could allow the understanding of the mechanisms involved in immune 
activation during nonpathogenic and pathogenic infections, to clarify 
how the reservoir immune response regulates Leishmania infection and 
how the parasites evade a sterilizing immune response.
The role of several species of rodents as wild reservoirs of Leishmania 
species is well known24,33,96,110. However, there are only a few studies that 
followed up experimentally infected wild hosts by Leishmania species, 
mostly due to the difficulties of managing wild mammals in captivity. 
To date the host-parasite interactions involved in persistent infections in 
different Leishmania reservoirs are unknown.
Sigmodon hispidus has been identified as Leishmania reservoir, 
however no studies of experimental infection have been carried out with 
this pathogen33. Currently Sigmodon hispidus is used as a model for 
the study of various infectious diseases, mainly caused by viruses and 
bacteria, due to its high susceptibility to a wide variety of pathogens80. 
A large number of cytokine and chemokine genes have been cloned and 
sequenced and monoclonal antibodies have been generated in order to 
facilitate its use as an experimental animal model. Recently, low levels of 
NO production and iNOS expression similar to human macrophages were 
found in Sigmodon hispidus infected with bacteria23. These similarities 
could explain the high susceptibility of this rodent to human pathogens.
Thrichomys laurentius is a South American caviomorph rodent 
formerly included in a monospecific genus, in which the importance of 
the retention of infection and transmission of Leishmania species has 
been established. These rodents were found infected with Leishmania 
species of different complexes – L. (L.) mexicana and L. donovani – in 
an endemic area of both visceral and tegumentary leishmaniasis in 
Brazil. Thrichomys laurentius was adapted to captivity and experimental 
patterns of L. infantum and L. braziliensis infections were identified in 
this rodent. Both Leishmania species demonstrated the ability to invade 
and persist in the viscera and skin of T. laurentius, yet no rodent displayed 
skin lesions, histological changes in skin, spleen or liver, nor clinical 
evidence of infection96.
In the Yucatan peninsula of Mexico, Peromyscus yucatanicus has been 
identified as primary reservoir of L. (L.) mexicana22,109. It has been adapted 
to the laboratory and a colony was established for experimental studies. 
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P. yucatanicus inoculated with 106 promastigotes of L. (L.) mexicana on 
the base of the tail reproduced both the clinical and histopathological 
picture of CL in humans, supporting its utility as a novel experimental 
model to study CL caused by L. (L.) mexicana104. Moreover 100% of P. 
yucatanicus inoculated with 102 (“low inoculum”) developed subclinical 
infection (absence of clinical signs and evidence of parasite´s DNA at 
the site of inocula) and when immunosupressed with cyclophosphamide 
a reactivation with the appearance of lesions was observed29. Nitric 
oxide production was documented in co-cultured macrophages and 
lymphocytes from P. yucatanicus with clinical and subclinical infection 
caused by L. (L.) mexicana64. Although NO production was observed in 
these wild rodents, they were unable to clear the infection, which differs 
with the response observed in murine models where the generation 
of NO is the main effector mechanism involved in the control of L. 
major infection. Similarly, the role of this cytotoxic molecule in the 
antileishmanial activity of human macrophages remains controversial42.
Recently cDNAs of Th1, Th2 and Th17 cytokines have been amplified 
from P. yucatanicus spleen cells by PCR using P. maniculatus primers 
cloned into TOPO TA cloning vector and sequenced63,111. These results 
strongly support employing P. maniculatus specific primers to study the 
kinetics of cytokines involved in the immune response against clinical and 
subclinical L. (L.) mexicana infection in P. yucatanicus. This approach 
will allow the quantifying and analyzing of the expression of important 
cytokines, transcription factors and cellular markers involved in the 
immune response to L. (L.) mexicana infection in a specific manner. It will 
also permit to determine the immune response leading to the clinical and 
subclinical infection in Yucatan deer mice and compare with the immune 
response observed in humans, in order to confirm its importance as an 
experimental model to study LCL caused by L. (L.) mexicana.
CONCLUSIONS
First of all, there is a worldwide agreement regarding the concept 
that experimental animal models are expected to mimic the pathological 
features and immunological responses observed in humans when 
exposed to a variety of Leishmania spp. with different pathogenic 
characteristics50. This approach deserves to be re-analyzed based on 
updated studies.
What does it mean to “mimic the patholgical features”? It is clear 
to date that the outcomes of the infection depend on a variety of factors 
in each particular laboratory animal including: a) the Leishmania spp. 
inoculated; b) the virulence of the parasite isolate used; c) the parasite 
stage, via, size, and route of the inoculum. In addition, the nature of 
each laboratory animal, i.e. the genetic makeup that relates to the 
immunological background, which plays an important role in host-
parasite realtionships. Moreover, when we say “leishmaniasis” as so “the 
leishmaniases”, we are referring to a group of diseases that are caused 
by different species of protozoan parasites of the genus Lesihmania. 
We have been trying (as it has been done in other pathologies such as 
“cancer”) to include different diseases as a single pathological entity. 
Therefore, shouldn’t we develop a different experimental animal model 
for each leishmaniasis?
It is well known that infection begins when an infected female sand 
fly takes a blood meal from a human host in a leishmaniasis endemic 
area. Following inoculation into the skin by the sand fly bite, the 
flagellated promastigotes penetrate into the macrophage, transform into 
amastigotes and multiply. The infected macrophage eventually bursts and 
the released parasites are able to infect new phagocytic cells. When the 
infected host is bitten by another female sand fly, parasites are ingested 
and the life cycle continues. The course of the disease is variable ranging 
from spontaneous healing to chronicity, but most infected individuals 
remain asymptomatic or subclinical. Therefore, there is a wide infection 
spectrum as a result of the parasite inoculation. As a consequence it is 
necessary to study the significance of subclinical infection in humans and 
other hosts. Therefore, when building a “good” animal model to study 
leishmaniasis immunology, should we consider all the possible outcomes 
of the Leishmania spp. infection, particularly subclinical infection?
With reference to the suggested requirement to “mimic immunological 
responses observed in humans” when exposed to a particular Leishmania 
spp., the problem becomes more complex if we consider that it varies 
depending on multiple factors according to present knowledge of the 
host-parasite interaction. In a recent work of the Working Group on 
research Priorities for Development of Leishmania Vaccines, a good 
review was made on vaccine trials in the last three decades, the profile 
of strategies, and animal models used in leishmaniasis trials108. The main 
questions raised encompassed issues concerning all of the leishmaniases. 
They have addressed the employment of live attenuated or genetically 
modified parasites, the role of vectors, and elucidation of protective 
immunity. Regarding the last issue, they considered it crucial to test 
vaccine candidates in different models using different species, and to 
test the effects of including salivary proteins of vectors. The major 
challenge is the absence of an experimental animal model that mimics 
the whole picture of human leishmaniasis, i.e. different subclinical and 
clinical outcomes and protective immune response. This situation leads 
to the necessary development of research studies focused mainly on 
building new animal models capable of evaluating the same criteria in 
both models and humans.
The use of wild rodents, primary reservoirs, as experimental models 
for studying Leishmania infection could be very useful to elucidate their 
role as reservoirs so as to improve our knowledge about the parasite-
vector and parasite-host relationship, in order to understand what happens 
in human Leishmania infections.
FINAL CONSIDERATIONS AND PERSPECTIVES
The use of experimental animal models remains a good alternative 
for designing immunological studies that, for ethical reasons, cannot 
be performed in humans. Certainly, the increased interest in studying 
the immune response against Leishmania infection in different 
animal models has contributed to our understanding of parasite-host 
relationship. However no model can develop all the possible outcomes 
of the Leishmania infection or entirely reproduce the disease in humans. 
Thus, there are still so many questions to answer in order to find control 
strategies or a successful vaccination program.
Although mouse model has widely contributed to the understanding 
of immune response against L. major infection many studies have 
demonstrated profound differences in the immune mechanisms related 
to infections with New World Leishmania species. Furthermore, 
visceral infection in mice does not mimic the pathological features 
and immunological responses observed in human cases. The hamster 
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result is a better model to study the progressive disease of visceralizing 
Leishmania spp. The lack of reagents for immunological analysis and 
the strong immunosuppression of the lymphoproliferative response in 
hamsters make difficult its use for the evaluation of vaccine candidates. 
The increased interest of researchers to use dogs as experimental 
models lies in the possibility of studying the immune response in 
natural infection. Since dogs are important reservoirs of visceralizing 
Leishmania, vaccination of these animals would constitute a major step 
towards the control of human infections. Finally, the use of monkeys has 
been explored for testing vaccine candidates, however little is known as 
to whether the immune response to Leishmania infection is similar to 
that observed in humans.
In order to obtain more meaningful data regarding immune response 
that parallels human disease it is very important to continue with the 
efforts in developing strategies to mimic natural transmission such as 
the use of low infectious doses, bioactive saliva and natural reservoir 
hosts to have a better approximation of the dynamics of natural infection. 
These approaches could contribute to developing improved experimental 
models for studying leishmaniasis and identifying possible targets to 
evaluate vaccine candidates.
RESÚMEN
Modelos animales para el estudio de la inmunología de la 
leishmaniosis
Las leishmaniosis siguen siendo un importante problema de 
salud pública a nivel mundial y se clasifican como categoría I por el 
programa TDR/WHO, debido principalmente a la ausencia de control. 
Muchos modelos experimentales tales como roedores, perros y monos 
han sido desarrollados, cada uno con características específicas, 
para caracterizar la respuesta inmune a las diferentes especies de 
Leishmania, sin embargo ninguno reproduce la patología observada 
en la enfermedad humana. La diversidad en los resultados obtenidos 
podría deberse en parte a que diferentes cepas de parásitos o especies 
están siendo examinadas, diferentes tejidos (cojinete plantar, oreja o 
base de la cola) han sido infectados y diferente número (“bajo” 1x102 
y “alto” 1x106) de promastigotes metacíclicos han sido inoculados. 
Recientemente, nuevos enfoques han sido propuestos con el fin de 
obtener datos más significativos en cuanto a la respuesta inmune del 
huésped y a la patogénesis, de tal forma que reproduzcan lo que ocurre 
en la enfermedad humana. El uso de la saliva del insecto y de un número 
de parásitos menor en las infecciones experimentales ha permitido 
reproducir la transmisión natural, identificar nuevas moléculas, así 
como mecanismos inmunes que deberían ser considerados en el 
diseño de vacunas y estrategias de control. Adicionalmente, se ha 
propuesto como una buena alternativa el uso de roedores silvestres 
como modelos experimentales tanto para el estudio de las relaciones 
huésped-patógeno como para probar nuevas vacunas. A la fecha, el uso 
de reservorios naturales para estudiar la infección por Leishmania ha 
sido un reto, debido a la carencia de reactivos inmunológicos para uso 
en roedores silvestres. Esta revisión describe los principales hallazgos 
inmunológicos ante la infección por Leishmania, en los diferentes 
modelos animales, destacando la importancia del uso de condiciones 
experimentales similares a la transmisión natural y de reservorios 
como modelos experimentales para el estudio de la inmunopatología 
de la enfermedad. 
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